Literature DB >> 2498562

The uptake of anticancer drugs by tumor tissues and lymph node and the effectiveness of postoperative adjuvant chemotherapy on survival time.

S Arima1, K Futami, H Toriya, H Shimura.   

Abstract

Forty-one patients with advanced gastric cancer underwent gastrectomy and the correlation between tissue uptake of the adjuvant drug and the prognosis were studied. The patients were preoperatively administered Tegafur (Futraful, Taiho Pharmaceutical Co. Ltd, Japan) and samples of tissue were obtained intraoperatively. 5-FU levels in the tumor and lymph nodes were measured by gas chromato-massfragmentography (GCMF). The patients in whom the 5-FU uptake by the tissues was measured and who were given over 60 g of Tegafur as postoperative adjuvant chemotherapy, were divided into two groups; namely, one group in whom the 5-FU uptake by the tumor tissue and lymph nodes was over 0.05 microgram/g and the other in whom the uptake was lower than 0.05 microgram/g. There were no significant differences in the background factors of either group. Each survival rate was calculated by the Kaplan-Meier method, and the generalized Wilcoxon method was used for statistical analysis. There was no statistically significant correlation between the 5-FU uptake by the tumor and the prognosis, however the 5-year survival rate in the group whose 5-FU uptake of the lymph nodes was over 0.05 microgram/g was statistically significant (p = 0.018).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498562     DOI: 10.1007/bf02471582

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  10 in total

1.  Study of adjuvant cancer chemotherapy by model experiments.

Authors:  G E MOORE; T KONDO
Journal:  Surgery       Date:  1958-07       Impact factor: 3.982

2.  Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years.

Authors:  T Hattori; K Inokuchi; T Taguchi; O Abe
Journal:  Jpn J Surg       Date:  1986-05

3.  Rseults of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence.

Authors:  H Imanaga; H Nakazato
Journal:  World J Surg       Date:  1977-03       Impact factor: 3.352

4.  Non-randomized controls in cancer clinical trials.

Authors:  E A Gehan; E J Freireich
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

5.  The general rules for The gastric cancer study in surgery.

Authors: 
Journal:  Jpn J Surg       Date:  1973-03

6.  [Study on the correlation between tissue uptake of anticancer agents and prognosis -- with special reference to Tegafur].

Authors:  S Arima; K Futami; M Kinashi; M Shigeta; H Jyozaki; H Shimura
Journal:  Gan To Kagaku Ryoho       Date:  1983-08

7.  Evaluation of extensive lymph node dissection for carcinoma of the stomach.

Authors:  Y Kodama; K Sugimachi; K Soejima; T Matsusaka; K Inokuchi
Journal:  World J Surg       Date:  1981-03       Impact factor: 3.352

8.  Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years.

Authors:  K Inokuchi; T Hattori; T Taguchi; O Abe; N Ogawa
Journal:  Cancer       Date:  1984-06-01       Impact factor: 6.860

9.  The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.

Authors:  F M Schabel
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

10.  High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur.

Authors:  T Marunaka; Y Umeno; K Yoshida; M Nagamachi; Y Minami; S Fujii
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

  10 in total
  1 in total

1.  Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.

Authors:  S Miyauchi; T Imaoka; T Utsunomiya; K Hayashi; M Kubo; T Kawaguchi; Y Matsui
Journal:  Jpn J Cancer Res       Date:  1994-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.